Compare ORN & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORN | XBIT |
|---|---|---|
| Founded | 1994 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.7M | 73.2M |
| IPO Year | 2007 | 2015 |
| Metric | ORN | XBIT |
|---|---|---|
| Price | $13.85 | $2.39 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $16.25 | N/A |
| AVG Volume (30 Days) | ★ 372.9K | 21.4K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 220.00 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $852,260,000.00 | N/A |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $7.83 | N/A |
| P/E Ratio | $114.75 | ★ N/A |
| Revenue Growth | ★ 7.01 | N/A |
| 52 Week Low | $6.44 | $2.09 |
| 52 Week High | $15.85 | $3.61 |
| Indicator | ORN | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 49.93 | 52.08 |
| Support Level | $12.98 | $2.15 |
| Resistance Level | $14.20 | $2.49 |
| Average True Range (ATR) | 0.76 | 0.06 |
| MACD | -0.16 | -0.02 |
| Stochastic Oscillator | 17.28 | 56.09 |
Orion Group Holdings Inc is a specialty construction company serving the infrastructure, industrial, and building sectors, providing services both on and off the water in the continental United States, Alaska, Canada, and the Caribbean Basin through its marine segment and its concrete segment. Its marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. The concrete segment generates maximum revenue and provides construction services for commercial, industrial, multi-family residential, and public projects, including the data center market.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.